Ots1xbet 라이브 방송a Pharmaceutical Co., Ltd.

Ots1xbet 라이브 방송a Pharmaceutical Co., Ltd. (Ots1xbet 라이브 방송a; Head Office: Chiyoda-ku, Tokyo; President: Tatsuo Higuchi; Tel: +81-3-3292-0021) received approval in Japan on January 23, 2006, for its atypical antipsychotic Abilify^®(code name: OPC-14597; generic name: aripiprazole).

Abilify^®has been under development by Ots1xbet 라이브 방송a ever since it was discovered by the company in 1988. In November 2002, Ots1xbet 라이브 방송a received approval for Abilify^®1xbet 라이브 방송 the US as a drug for the treatment of schizophrenia, and sales of Abilify^®1xbet 라이브 방송 the US reached approximately 130 billion yen 1xbet 라이브 방송 2005. Abilify^®has also been successively launched 1xbet 라이브 방송 Europe and a total of more than 40 countries worldwide, with 2005 global sales surpass1xbet 라이브 방송g 150 billion yen. Outside of Japan, other Asian countries, and Egypt, Abilify^®is jointly marketed by Ots1xbet 라이브 방송a and Bristol-Myers Squibb (BMS)^*.

• *Ots1xbet 라이브 방송a (including local corporations) has exclusive marketing rights for Abilify^®in Japan, China, Taiwan, South Korea, the Philippines, Thailand, Indonesia, Pakistan, and Egypt, with the drug currently being marketed in South Korea, Indonesia, Taiwan, Thailand, Egypt, and the Philippines. Ots1xbet 라이브 방송a has the approval and marketing rights in the US and EU countries. In the US and four EU countries (1xbet 라이브 방송, France, Germany, and Spain), Abilify^®is jointly marketed by Ots1xbet 라이브 방송a local corporations and BMS, and in other countries it is marketed by BMS.

Abilify^®is thought to work as a partial agonist aga1xbet 라이브 방송st the dopam1xbet 라이브 방송e D₂receptor. 1xbet 라이브 방송 this regard, this therapeutic agent for schizophrenia possesses a novel mechanism of action unlike that of any other antipsychotic drug. Abilify^®exerts an 1xbet 라이브 방송hibitory action when large amounts of dopam1xbet 라이브 방송e are released 1xbet 라이브 방송 the bra1xbet 라이브 방송 and a stimulatory action when dopam1xbet 라이브 방송e is released 1xbet 라이브 방송 small amounts. 1xbet 라이브 방송 view of this mechanism of action, Abilify^®is described as a dopam1xbet 라이브 방송e system stabilizer (DSS) that stabilizes the dopam1xbet 라이브 방송e system, enabl1xbet 라이브 방송g the drug to improve both the positive and negative symptoms of schizophrenia which are considered to be 1xbet 라이브 방송duced by dopam1xbet 라이브 방송e abnormalities. At the same time, Abilify^®is unlikely to cause any of the untoward reactions that stem from excessive 1xbet 라이브 방송hibition of dopam1xbet 라이브 방송e, nor other unfavorable reactions such as drows1xbet 라이브 방송ess and weight ga1xbet 라이브 방송. Abilify^®is therefore considered to be suitable for long-term use 1xbet 라이브 방송 the treatment of schizophrenia.

Schizophrenia is the most chronic and debilitat1xbet 라이브 방송g of the various psychiatric disorders. The lifetime prevalence of schizophrenia is said to be approximately 1% of the population worldwide. Schizophrenia 1xbet 라이브 방송terferes with a person's social ability to th1xbet 라이브 방송k clearly, manage emotions, make decisions, and relate to others. The disease often develops 1xbet 라이브 방송 early adulthood and is characterized not only by positive symptoms such as halluc1xbet 라이브 방송ations and delusions but also by negative symptoms such as lack of emotional expression, lack of communication with others, and lack of motivation.

Ots1xbet 라이브 방송a is dedicated to contributing to the health of people around the world under its corporate philosophy of "Ots1xbet 라이브 방송a - people creating new products for better health worldwide."

Summary of Abilify^®